Stage II/III Colorectal Cancer Recurrence

Launched by CITY OF HOPE MEDICAL CENTER · Mar 15, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on helping doctors predict whether colorectal cancer will come back in patients who have already been treated for stage II or III colorectal cancer. Specifically, the study aims to develop a test that looks at the DNA in a patient's cells to see if it can give clues about the risk of cancer recurrence after they have completed their chemotherapy treatment.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have had high-risk stage II or stage III colorectal cancer. They must have undergone surgery to remove the cancer and have received chemotherapy afterward, with no signs of cancer at the time they join the study. Participants will need to provide written consent to take part in the trial. This research could be important for improving the way doctors monitor and manage patients who have survived colorectal cancer, helping them catch any potential recurrence early on.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
• • Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
• • Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
• • Confirmed cancer-free survivorship confirmed at the time of study inclusion.
• Exclusion Criteria:
• • Lack of written informed consent.
• • Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
• • Hereditary colorectal cancer syndromes (identified through genetic testing)
• • Inflammatory bowel diseases